We're bringing you highlights from the 67th ASH Annual Meeting with a summary of selected scientific sessions on CML, a prospective study testing nilotinib vs. imatinib with early switch to improve TFR, and the first prospective trial of asciminib with dose escalation as second-line therapy.

🌟 Oral Abstract Session: CML clinical & epidemiological - Therapeutic agents to enhance patient outcomes

Chairs: Elisabetta Abruzzese (Rome) - Vivian Oehler (Seattle)
This clinical session presented major advances in novel TKIs, frontline optimisation strategies, real-world outcomes in blast-phase CML, and next-generation approaches to achieving deeper and safer molecular responses. Across six presentations, investigators showcased: promising phase 1 data for TERN-701 and TGRX-678, updated results from a frontline asciminib combination trial, the largest US analysis of blast-phase management, a prospectie study testing nilotinib vs. imatinib with early switch to improve TFR, and the first prospective trial of asciminib with dose escalation as second-line therapy. 

Collectively, the studies demonstrated:

• High efficacy and favourable safety of new agents even in heavily pretreated or T315I-mutated patients,
• Asciminib’s expanding role in both frontline combinations and second-line therapy,
• The persistent challenge and therapeutic needs of blast-phase CML,
• The importance of risk-adapted frontline selection to improve long-term TFR outcomes,
• And the feasibility of dose escalation strategies with asciminib to address suboptimal responders.

Our key takeaways from the presentations:

Read more